Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908577 · ClinicalTrials.gov registry record · Phase 1
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 254
- Enrollment target
- 4
- Study locations
NCT06908577: Completed Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
NCT06908577 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 254 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (303% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06908577, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 254 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
Primary Outcome
To compare the PK exposure following single SC administration of tozorakimab using AI and APFS devices in healthy participants.
Conditions Studied
Interventions
- DRUG Tozorakimab
- DEVICE Autoinjector (AI) Device
- DEVICE Accessorised Prefilled Syringe (APFS) Device
Study Locations (4)
Other
- Research Site - Berlin
- Research Site - Harrow
California
- Research Site - Glendale
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 1 |
What the finished NCT06908577 record still lists
NCT06908577 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (303% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Tozorakimab is the first listed.
NCT06908577 reports a single indexed study location in Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06908577 about?
NCT06908577 is a clinical study titled "An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab". The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
What is the current status of trial NCT06908577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2025-04-07. Estimated completion is 2025-11-25.
What conditions does trial NCT06908577 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06908577?
The interventions under investigation include: Tozorakimab (DRUG), Autoinjector (AI) Device (DEVICE), Accessorised Prefilled Syringe (APFS) Device (DEVICE).
Who is sponsoring clinical trial NCT06908577?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908577 being conducted?
This trial has 4 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06908577's enrollment target sits among peer trials
254 6th of 119 higher than 114 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI